Results 81 to 90 of about 57,561 (262)
Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom
British Journal of Haematology, EarlyView.Trametinib (MEK inhibitor) shows efficacy in refractory and high‐risk adult histiocytic neoplasms. At a median follow‐up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).
Rodothea Amerikanou +15 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard +10 more
wiley +1 more source
CHILD WITH JOINT PAIN – CLINICAL VIGNETTES
Slovenska pediatrijaJoint pain is a common clinical symptom in children with a broad and diverse etiology – ranging from benign, self-limiting conditions to serious and potentially life-threatening diseases.
Maša Bizjak
doaj +1 more source
Arthralgia (arthritis).Advances on diagnosis and treatment.II...Epidemiology of arthralgia.
Nihon Naika Gakkai Zasshi, 1994 関節痛を主訴とするリウマチ病の疫学研究の中から, RA,変形性関節症,肩痛症,強直性脊椎炎,若年性関節リウマチ,痛風,結合組織病, Lyme病について,日本と外国との成績を比較して紹介した.変形性関節症,痛風,若年性関節リウマチでは,外国と大差はないが,慢性関節リウマチ,強直性脊椎炎では低頻度で,結合組織病ではむしろ多いかもしれない.環境因子,素因についての研究は,今後の進展を期待する.
openaire +2 more sources
Diagnosis and management of neutropenia in adults: Expert guidance
British Journal of Haematology, EarlyView.Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte +5 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
Human brain matters: Navigating the neuropathology of COVID‐19
Brain Pathology, EarlyView.Severe COVID‐19 is associated with vascular dysregulation and chronic neuroinflammation, leading to axonal injury and neurodegeneration. In long COVID or PASC, persistent alterations in neuroimaging and biofluid biomarkers reflect ongoing neuronal damage and neuroinflammation, contributing to long‐term neurological symptoms including fatigue, cognitive
Juliana M. Nieuwland +4 more
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Cell Proliferation, EarlyView.Schematic diagram for the experimental design for adaptome immune repertoire analysing Dampness ZHENG across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis. ABSTRACT Autoimmune diseases, including psoriasis (Ps), rheumatoid arthritis (RA) and ulcerative colitis (UC), pose significant health burdens worldwide.
Lipeng Tang +21 more
wiley +1 more source